Phathom Pharmaceuticals earnings were -$99.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest PHAT earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$17.6M, down 42.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PHAT reported annual earnings of -$221.2M, with -33.8% growth. The next PHAT earnings date is Oct 29, 2026.
Phathom Pharmaceuticals Earnings Reports & History FAQ
What were Phathom Pharmaceuticals's earnings last quarter?
On PHAT's earnings call on Jul 30, 2026, Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q2 2026 earnings per share (EPS) of -$0.21, up 80% year over year. Total PHAT earnings for the quarter were -$17.58 million. In the same quarter last year, Phathom Pharmaceuticals's earnings per share (EPS) was -$1.05.
When does Phathom Pharmaceuticals report earnings?
The next PHAT earnings call is Oct 29, 2026. Add PHAT to your watchlist to be reminded of Phathom Pharmaceuticals's next earnings date.
Is Phathom Pharmaceuticals profitable or losing money?
As of the last Phathom Pharmaceuticals earnings report, Phathom Pharmaceuticals is currently losing money. Phathom Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$99.07 million, a 69.99% decrease year over year.
What was PHAT's earnings growth in the past year?
As of Phathom Pharmaceuticals's earnings date in Jul 30, 2026, Phathom Pharmaceuticals's earnings has grown year over year. PHAT earnings in the past year totalled -$99.07 million.
What are Phathom Pharmaceuticals's earnings expectations?
The current EPS estimate for Phathom Pharmaceuticals's earnings report in Oct 29, 2026 is -$0.01.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.